These results suggest that PI3K signaling activation characterizes a specific subpopulation of patients with DLBLC whose prognosis could be further defined by IQGAP3, as its expressional level demarcates RAS activity in lymphoma cells. The gene discussed is PIK3CD; the disease is lymphoma.